Hikma Pharmaceuticals PLC (LON:HIK) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Hikma Pharmaceuticals PLC (LON:HIK) has received a consensus rating of “Moderate Buy” from the six research firms that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month price target among analysts that have covered the stock in the last year is GBX 2,250 ($29.67).

Several research analysts have issued reports on HIK shares. Berenberg Bank increased their price objective on Hikma Pharmaceuticals from GBX 2,000 ($26.37) to GBX 2,100 ($27.69) and gave the stock a “hold” rating in a research report on Monday, August 12th. Barclays reiterated an “equal weight” rating and issued a GBX 2,000 ($26.37) price objective on shares of Hikma Pharmaceuticals in a research report on Tuesday, May 7th. Finally, Deutsche Bank Aktiengesellschaft reissued a “buy” rating and issued a GBX 2,750 ($36.27) target price on shares of Hikma Pharmaceuticals in a report on Tuesday, June 18th.

Hikma Pharmaceuticals Trading Down 0.5 %

LON:HIK opened at GBX 1,983 ($26.15) on Friday. The stock’s 50 day simple moving average is GBX 1,918.23 and its 200-day simple moving average is GBX 1,921.71. Hikma Pharmaceuticals has a 12-month low of GBX 1,711 ($22.56) and a 12-month high of GBX 2,216 ($29.22). The firm has a market cap of £4.40 billion, a P/E ratio of 3,050.77, a PEG ratio of 2.38 and a beta of 0.40. The company has a current ratio of 1.66, a quick ratio of 1.27 and a debt-to-equity ratio of 55.48.

Hikma Pharmaceuticals Cuts Dividend

The firm also recently declared a dividend, which will be paid on Friday, September 20th. Shareholders of record on Thursday, August 15th will be paid a $0.32 dividend. This represents a yield of 1.37%. The ex-dividend date of this dividend is Thursday, August 15th. Hikma Pharmaceuticals’s payout ratio is 9,538.46%.

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.